New GMPs Will Have Limited Impact On Listed Companies
This article was originally published in PharmAsia News
Executive SummaryWith the official release of China's updated Good Manufacturing Practice standards (GMPs) expected this month, some analysts predict limited impact on listed drug companies, based on a draft version released earlier this year
You may also be interested in...
Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.